-
13 February 2024
-
13 February 2024
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
PARIS, FRANCE, 13 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorour...
-
15 November 2024
-
15 November 2024
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Asso...
-
27 April 2023
-
27 April 2023
-
31 August 2023
- 2 mins read
-
31 August 2023
- 2 mins read
Managing Post-Stroke Spasticity: Hub’s Story
Hub experienced a hemorrhagic stroke in 2021 as a result of bleeding in the brain. Like many stroke survivors, Hub experiences spasticity, a condition in which muscles contract uncontrollably leading to pain, stiffness and limited movement. As a father of ...
-
26 April 2024
- 3 mins read
-
26 April 2024
- 3 mins read
Measuring pancreatic cancer care in moments
Emad Abdelnaby, Senior Vice President, Oncology Franchise Head at Ipsen shares learnings from Dr. Maen Hussein of Florida Cancer Specialists & Research Institute about his approach to treating pancreatic cancer...
-
24 July 2023
-
24 July 2023
Media
...
-
09 May 2023
-
09 May 2023
-
11 May 2023
-
11 May 2023
-
16 May 2023
-
16 May 2023
-
09 May 2023
-
09 May 2023